Search Results - "Viardot, A."

The Effects of Weight Loss and Gastric Banding on the Innate and Adaptive Immune System in Type 2 Diabetes and Prediabetes by Viardot, A., Lord, R. V., Samaras, K.

“…Context: Obesity-related chronic inflammation is implicated in the pathogenesis of type 2 diabetes (T2D). Objective: The objective of the study was to…”
Get full text

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL by Murawski, N., Pfreundschuh, M., Zeynalova, S., Poeschel, V., Hänel, M., Held, G., Schmitz, N., Viardot, A., Schmidt, C., Hallek, M., Witzens-Harig, M., Trümper, L., Rixecker, T., Zwick, C.

“…To improve outcome of elderly patients with diffuse large B-cell lymphoma, dose-dense rituximab was evaluated in the prospective DENSE-R-CHOP-14 trial…”
Get full text

Randomised clinical study: inulin short‐chain fatty acid esters for targeted delivery of short‐chain fatty acids to the human colon by Polyviou, T., MacDougall, K., Chambers, E. S., Viardot, A., Psichas, A., Jawaid, S., Harris, H. C., Edwards, C. A., Simpson, L., Murphy, K. G., Zac‐Varghese, S. E. K., Blundell, J. E., Dhillo, W. S., Bloom, S. R., Frost, G. S., Preston, T., Tedford, M. C., Morrison, D. J.

“…Summary Background Short‐chain fatty acids (SCFA) produced through fermentation of nondigestible carbohydrates by the gut microbiota are associated with…”
Get full text

Obesity is associated with activated and insulin resistant immune cells by Viardot, A., Heilbronn, L. K., Samocha-Bonet, D., Mackay, F., Campbell, L. V., Samaras, K.

“…Background Obesity and type 2 diabetes mellitus are characterized by insulin resistance and ‘low‐grade inflammation’; however, the pathophysiological link is…”
Get full text

Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM) by Kumar, S. S., McManus, H., Radovich, T., Greenfield, J. R., Viardot, A., Williams, K. M., Cronin, P., Day, R. O.

“…Purpose The management of type 2 diabetes mellitus (T2DM) is complex. The aim of this work is to explore factors that predict the need for add-on therapy in…”
Get full text

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia by Zugmaier, G, Topp, M S, Alekar, S, Viardot, A, Horst, H-A, Neumann, S, Stelljes, M, Bargou, R C, Goebeler, M, Wessiepe, D, Degenhard, E, Gökbuget, N, Klinger, M

Get full text

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis by Pouyiourou, M., Meyer, A., Stroux, A., Viardot, A., La Rosée, P., Maschmeyer, G., Kämpfe, D., Kahl, C., Vucinic, V., Monecke, A., Hirt, C., Weber, T., Meissner, J., Witzens-Harig, M., Böttcher, S., Schmalenberg, H., Marks, R., Prange-Krex, G., Kroschinsky, F., Hauf, E., Keller, U., Koch, K., Klapper, W., Herold, M., Scholz, Christian W.

“…Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. Grade FL3A frequently coexists with FL1-2 (FL1-2-3A). Based…”
Get full text

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group by Ferdinandus, J., Moccia, A. A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Fuchs, M., Behringer, K., Schneider, G., Rosenwald, A., Klapper, W., Eich, H. T., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A., Borchmann, P.

Get full text

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL by Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Ferdinandus, J., Fuchs, M., Rosenwald, A., Klapper, W., Eich, H., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A.

Get full text

family history of type 2 diabetes increases risk factors associated with overfeeding by Samocha-Bonet, D, Campbell, L. V, Viardot, A, Freund, J, Tam, C. S, Greenfield, J. R, Heilbronn, L. K

“…Aims/hypothesis The purpose of the study was to test prospectively whether healthy individuals with a family history of type 2 diabetes are more susceptible to…”
Get full text

Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH) by WESSENDORF, S, BARTH, T. F. E, SCHWAENEN, C, VIARDOT, A, MUELLER, A, KESTLER, H. A, KOHLHAMMER, H, LICHTER, P, BENTZ, M, DÖHNER, H, MÖLLER, P

“…Primary mediastinal B-cell lymphoma (PMBL) is an aggressive extranodal B-cell non-Hodgkin's lymphoma with specific clinical, histopathological and genomic…”
Get full text

CLINICAL PRESENTATION AND MOLECULAR CHARACTERISTICS OF CUTANEOUS DLBCL by Bloehdorn, J., Weissinger, S.E., Sindrilaru, A., Peters, T., Möller, P., Marienfeld, R., Viardot, A.

Get full text

DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL NON‐HODGKIN LYMPHOMA by Viardot, A., Hess, G., Bargou, R., Morley, N.J., Gritti, G., Iskander, K., Cohan, D., Zhang, A., Franklin, J., Coyle, L.

Get full text

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis by Lerch, K., Meyer, A. H., Stroux, A., Hirt, C., Keller, U., Viardot, A., Marks, R., Schreiber, S., Pezzutto, A., Scholz, C. W.

“…Transformation of follicular lymphoma (FL) into aggressive disease and relapse of de novo diffuse large B cell lymphoma (DLBCL) are considered highly…”
Get full text

Trends in metformin utilisation and dose appropriateness in Australia by Moon, J., Kumar, S. S., Graham, G. G., Baysari, M. T., Williams, K. M., Chen, W., Viardot, A., Greenfield, J. R., Day, R. O.

“…Purpose The study aimed to (1) determine the trends in the utilisation of metformin in Australia, (2) determine the appropriateness of metformin dosing in an…”
Get full text

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) by Fowler, N. H., Dickinson, M., Martinez‐Lopez, J., Kolstad, A., Schuster, S. J., Dreyling, M., Ghosh, M., Harigae, H., Kersten, M. José, Bachy, E., Popplewell, L., Chavez, J. C., Ho, P. J., Butler, J., Kato, K., von Tresckow, B., Ferreri, A. J. M., Simón, J. A. P., Patten, P. E. M., Andreadis, C., Riedell, P. A., McGuirk, J. P., Nastoupil, L. J., Teshima, T., Offner, F., Petzer, A., Viardot, A., Zinzani, P. L., Malladi, R., Zhang, J., Tiwari, R., Bollu, V., Masood, A., Thieblemont, C.

Get full text

INTENSIVE IMMUNOCHEMOTHERAPY (R‐CHOEP) VS HIGH‐DOSE IMMUNOCHEMOTHERAPY (R‐MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA: A 10‐YEAR LONG‐TERM FOLLOW‐UP by Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glaß, B., Hänel, M., Trümper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Metzner, B., Kroschinsky, F., Staiger, A.M., Ott, G., Rosenwald, A., Löffler, M., Lenz, G., Schmitz, N.

Get full text

P1189: INITIAL SAFETY RUN‐IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by McMillan, A., Haioun, C., Sancho, J.‐M., Viardot, A., Rodriguez Izquierdo, A., Donato Martin, E. M., García‐Sancho, A. M., Sandoval‐Sus, J., Tilly, H., Vandenberghe, E., Hirata, J., Choudhry, P., Chang, Y. M., Musick, L., Matasar, M.

Get full text

S106: UBTF‐ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEFINES NOVEL HIGH‐RISK ALL SUBTYPE AMENABLE TO MRD‐BASED TREATMENT INTENSIFICATION by Bastian, L., Hartmann, A., Beder, T., Hänzelmann, S., Kässens, J., Bultmann, M., Höppner, M. P., Franzenburg, S., Wittig, M., Franke, A., Nagel, I., Spielmann, M., Reimer, N., Busch, H., Schwartz, S., Steffen, B., Viardot, A., Döhner, K., Kondakci, M., Wulf, G., Wendelin, K., Renzelmann, A., Kiani, A., Trautmann, H., Neumann, M., Gökbuget, N., Brüggemann, M., Baldus, C.

Get full text

FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY by Tournilhac, O., Truemper, L., Ziepert, M., Bouabdallah, K., Nickelsen, M., Maury, S., Reimer, P., Jaccard, A., Herr, W., Wilhelm, M., Cartron, G., Wulf, G., Sanhes, L., Dreger, P., Lamy, T., Kroschinsky, F., Lindemann, H., Roussel, M., Viardot, A., Sibon, D., Delmer, A., De Leval, L., Damaj, G.L., Gisselbrecht, C., Gaulard, P., Rosenwald, A., Friedrichs, B., Altmann, B., Schmitz, N.

Get full text